View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines

Samsung, Memory: Samsung expects CQ3 profit to grow 158% to ~12 Tr Won ($8.5B)View: Samsung yesterday announced its 3Q operating profit is expected to grow ~32% Y/Y to 12.1 trillion won ($8.5B), marking its highest levels since 2Q22 and far exceeding consensus of ~10 trillion won. Although detailed

Dan Salmon
  • Dan Salmon

AI Exec Series Recap: Character.ai on competing with RBLX & Insta, and...

Last week, we hosted the latest edition of our AI Executive Speaker Series with Karan Anand, CEO of Character.ai. The replay is HERE and in the report we cover key takeaways from the conversation, including: 1. Character.ai today & what lies ahead: from AI research to competing with RBLX 2. The ad opportunity & how Character leverage’s GOOGL’s AdMob, APP & META 3. Character’s work with open-source models from META’s Llama to DeepSeek to Qwen 4. Industry AI investment/returns (GOOGL, META, OpenAI...

 PRESS RELEASE

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIM...

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare catego...

 PRESS RELEASE

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neuro...

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome – An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status at 3 years in the open-label extension studies reported by clinicians and caregivers in 95% of patients treated with zorevunerse...

Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines

Samsung, NVDA: Jensen Huang reportedly confirms Samsung’s HBM3e qualView: Per News1 Korea, Jensen has personally informed Samsung that its HBM3e has passed NVIDIA’s quality qualification tests and that NVDA intends to place orders. The two companies, in turn, are now reportedly fine-tuning details

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...

Dan Salmon
  • Dan Salmon

AWS/GCP: How long does it take to pay off an XPU?

We take a closer look at how long it takes for AWS and GCP to pay back the investment in both GPUs and custom chips (TPUs and Trainium) on both a revenue and contribution margin basis, using our estimates of per-chip costs and realized pricing for each of AWS and GCP.

Dan Salmon
  • Dan Salmon

GOOGL/AMZN/META: Updated AI D&A and Lower META AI RO

we've updated our bottom-up AI depreciation analysis for GOOGL, AMZN and META following our latest AI capex update (see HERE).

 PRESS RELEASE

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecane...

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months TOKYO and CAMBRIDGE, Mass.,...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch